
Nkarta NKTX
€ 1.57
10.06%
Nkarta Operativer Cashflow | NKTX
Operativer Cashflow Jährlich Nkarta
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -88.7 M | -99.7 M | -86.2 M | -57 M | -67.9 M | -43.5 M | -18.4 M | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -18.4 M | -99.7 M | -65.9 M |
Operativer Cashflow Vierteljährlich Nkarta
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -24.2 M | -28.2 M | -21.6 M | -18.7 M | -18.8 M | -29.6 M | -24.8 M | -24.5 M | -21.9 M | -28.5 M | -23.4 M | -20.3 M | -21.8 M | -20.8 M | -7.33 M | -14.8 M | -16.6 M | -18.3 M | -17.6 M | -18.3 M | -32.1 M | -14.6 M | -12.9 M | -30.7 M | -18.5 M | -8.29 M | - | -11.7 M | -7.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -7.08 M | -32.1 M | -19.8 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
BiomX
PHGE
|
-26.4 M | $ 1.85 | 14.2 % | $ 3.02 M | ||
|
Pieris Pharmaceuticals
PIRS
|
-25 M | - | -15.58 % | $ 1.22 B | ||
|
Plus Therapeutics
PSTV
|
-20.8 M | - | - | $ 301 M | ||
|
Pluristem Therapeutics
PSTI
|
-19.6 M | - | -1.9 % | $ 33.3 M | ||
|
Qualigen Therapeutics
QLGN
|
-6.95 M | - | 5.59 % | $ 1.16 M | ||
|
Qilian International Holding Group Limited
QLI
|
-2.37 M | - | -6.08 % | $ 184 M | ||
|
Cassava Sciences
SAVA
|
-32.3 M | - | - | $ 110 M | ||
|
Selecta Biosciences
SELB
|
-73.9 M | - | -8.69 % | $ 126 M | ||
|
Sangamo Therapeutics
SGMO
|
-97.2 M | - | - | $ 50.4 M | ||
|
Salarius Pharmaceuticals
SLRX
|
-4.83 M | - | - | $ 2.64 M | ||
|
Sensei Biotherapeutics
SNSE
|
-20.5 M | - | - | $ 17.5 M | ||
|
Sonnet BioTherapeutics Holdings
SONN
|
-12.8 M | - | - | $ 826 K | ||
|
Synthetic Biologics
SYN
|
-16.7 M | - | 1.32 % | $ 16.2 M | ||
|
Synlogic
SYBX
|
-4.36 M | - | - | $ 7.07 M | ||
|
Virios Therapeutics, LLC
VIRI
|
-15.6 M | - | 2710.01 % | $ 72.9 M | ||
|
Vallon Pharmaceuticals
VLON
|
-10.2 M | - | -6.47 % | $ 5.76 M | ||
|
Vaxart
VXRT
|
-2.05 M | - | -25.06 % | $ 46.3 M | ||
|
XOMA Corporation
XOMA
|
2.87 M | - | - | $ 485 M | ||
|
Repare Therapeutics
RPTX
|
-76.4 M | - | - | $ 112 M | ||
|
Sesen Bio
SESN
|
-59.9 M | - | 7.29 % | $ 127 M | ||
|
Windtree Therapeutics
WINT
|
-15.4 M | - | - | $ 26.8 M | ||
|
Trean Insurance Group
TIG
|
109 M | - | - | $ 316 M | ||
|
SQZ Biotechnologies Company
SQZ
|
-83.5 M | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
-9.12 M | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
-13.5 M | - | - | $ 13 M | ||
|
Lyra Therapeutics
LYRA
|
-28.9 M | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-84.3 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
-22.7 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
-88.6 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-24.7 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-186 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-83.3 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-186 M | $ 4.21 | 4.99 % | $ 653 M | ||
|
AbbVie
ABBV
|
19 B | $ 291.22 | 1.06 % | $ 515 B | ||
|
22nd Century Group
XXII
|
-7.72 M | $ 1.56 | -19.17 % | $ 287 K | ||
|
Axon Enterprise
AXON
|
211 M | $ 313.68 | -18.01 % | $ 24.5 B | ||
|
Biogen
BIIB
|
2.2 B | $ 248.51 | 1.88 % | $ 36.4 B | ||
|
BioLineRx Ltd.
BLRX
|
-8.07 M | $ 1.73 | -2.15 % | $ 4.26 B | ||
|
Theratechnologies
THTX
|
2.38 M | - | - | $ 83.9 M | ||
|
Exelixis
EXEL
|
884 M | $ 69.55 | 1.22 % | $ 18.9 B | ||
|
Geron Corporation
GERN
|
-111 M | $ 0.99 | 3.97 % | $ 660 M | ||
|
Gilead Sciences
GILD
|
10 B | $ 166.9 | -0.4 % | $ 208 B | ||
|
Grifols, S.A.
GRFS
|
902 M | $ 8.46 | -0.12 % | $ 5.75 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
524 M | $ 155.97 | -0.44 % | $ 20.4 B | ||
|
InflaRx N.V.
IFRX
|
-35.3 M | $ 1.31 | -3.69 % | $ 88.1 M |